ASH 2022 | Acalabrutinib in combination with umbralisib and ublituximab in previously untreated MCL
Geoffrey Shouse
• 12 Dec 2022
In this video, Geoffrey Shouse, DO, PhD, City of Hope Comprehensive Cancer Center, Duarte, CA, shares some results from a Phase II study evaluating the safety and efficacy of acalabrutinib in combination with umbralisib and ublituximab (AU2) for patients with previously untreated mantle cell lymphoma (MCL; NCT04783415). This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Kite Pharma: Speakers Bureau; Beigene Inc USA: Honoraria.
